No title
Ovarian cancer (OC) represents one of the most prevalent and lethal malignancies in women, with a need for novel treatments. A large obstacle in the development of OC therapies is the poor translation between preclinical and clinical results, partially attributable to the use of unsuitable models for drug screening. Common models such as cell lines, organoids, spheroids, tumor-on-a-chip, and anima
